Table 1.
Alzheimer’s disease (AD) model and effects of quercetin on memory.
| AD Model | Dose and Duration of Quercetin | Effects | References |
|---|---|---|---|
| 3 µg/µL of Aβ1–42 injection into bilateral intracerebroventricular zones of rats | 40 mg/kg/day orally, one month | improvement of spatial learning and memory. increase of the number of doublecortin (DCX)-expressing cells in the dentate gyrus. increase of BDNF expression. |
[65] |
| 3xTg-AD mice | 25 mg/kg intraperitoneal injection, every 48 h for three months | reduction of Iba-1 and iNOS microglial immunoreactivity in the CA1 area of the hippocampus. decreased fluorescence intensity of Aβ. |
[66] |
| 3xTg-AD mice | 25 mg/kg intraperitoneal injection, every 48 h for three months | decrease of Aβ, tauopathy, astrogliosis, and microgliosis in the hippocampus and the amygdala. improvement of spatial learning, memory, and anxiety. |
[67] |
| APPSWE/PS1dE9 mice | 40 mg/kg/day orally, 16 weeks | improvement of mitochondria dysfunction. increase AMPK activity. |
[68] |
| Senescence Accelerated Mouse-Prone 8 (SAMP8) mice | 25 mg/kg quercetin-loaded nanoparticles (NPQ) orally, every two day, two months | improvement of the cognition and memory impaiments by NPQ. decreased expression of the hippocampal GFAP expression. |
[69] |
| pentylenetrazole (PTZ)-induced cognitive impairment of zebrafish | 10 mg/kg solid lipid nanoparticle of quercetin, single intraperitoneal injection | inhibition of PTZ-induced cognitive impairment and acetylcholinesterase activity. | [70] |
| human Aß expressing Drosophila | 0.44 g/L in standard sugar-yeast medium, dietary supplementation of quercetin, 10 days | inhibition of Cyclin B expression. extended lifespan. |
[71] |